Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROMYCIN ESTOLATE versus TAO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROMYCIN ESTOLATE versus TAO.
ERYTHROMYCIN ESTOLATE vs TAO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin estolate is a macrolide antibiotic that reversibly binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step. It may also exhibit immunomodulatory and anti-inflammatory effects.
Troleandomycin (TAO) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide chain elongation.
250-500 mg orally every 6-12 hours
250-500 mg orally every 6 hours or 500 mg intravenously every 6 hours. For severe infections, up to 500 mg every 6 hours IV.
None Documented
None Documented
Approximately 1.5-2 hours in normal adults; prolonged to 5-6 hours in end-stage renal disease.
Terminal elimination half-life of 12-24 hours in adults; may be prolonged in hepatic impairment (up to 40-60 hours) and in neonates (2-5 days).
Primarily hepatic via biliary excretion into feces; approximately 2-5% excreted unchanged in urine. <5% renal elimination.
Primarily hepatic metabolism with <10% excreted unchanged in urine; approximately 30% excreted in feces via bile.
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic